A retrospective study of 18 children and adolescents treated with CT-guided percutaneous cryoablation for osteoid osteoma found complete technical and clinical success at one month, with rapid pain relief and no major procedure-related adverse events, Pediatric Radiology reported on Nov. 19.
- Technical success was achieved in all 18 procedures performed between December 2022 and May 2025.
- All patients were pain-free within 14 days and had stopped analgesics by one month.
- The median radiation dose-length product was 158 mGy·cm (with an interquartile range of 100–300).
- No Society of Interventional Radiology–classified adverse events were observed.
The single-center study enrolled 18 consecutive patients — 10 males, median age 13.5 years (range 6–17) — who underwent CT-guided cryoablation at the University Hospital of Saint-Étienne, Faculty of Medicine, Saint-Étienne, France, between December 2022 and May 2025. Clinical success at 1 month and technical success were the primary outcomes. Secondary outcomes included Society of Interventional Radiology (SIR)-classified adverse events, pain evolution assessed using the numeric rating scale (NRS), analgesic use, procedure duration, and dose-length product.
The study was authored by Sylvain Grange, Department of Radiology, University Hospital of Saint-Étienne, Faculty of Medicine, Saint-Étienne, France; Rémi Grange, Department of Radiology, University Hospital of Saint-Etienne, Faculty of Medicine, Saint-Etienne, France; Nicolas Stacoffe, Department of Radiology, Hospices Civils de Lyon, Lyon, France; Kevin Perez, Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada; Hassan Al Khoury Salem, Department of Pediatric Surgery, University Hospital of Saint-Etienne, Faculty of Medicine, Saint-Etienne, France; Elie Haddad, Department of Pediatric Surgery, University Hospital of Saint-Etienne, Faculty of Medicine, Saint-Etienne, France; Louis-Martin Boucher, Department of Diagnostic Radiology, McGill University Health Centre (MUHC – Glen), Royal Victoria Hospital, Montreal, Canada; Jean-Pierre Pelage, Department of Diagnostic Radiology, McGill University Health Centre (MUHC – Glen), Royal Victoria Hospital, Montreal, Canada; and Natalia Gorelik, Department of Diagnostic Radiology, McGill University Health Centre (MUHC – Glen), Royal Victoria Hospital, Montreal, Canada.
Technical success, defined as successful probe placement and ablation cycle completion, was achieved in all 18 procedures (18/18). Clinical success, defined as complete pain relief and discontinuation of analgesics, was reached in all patients by the 1-month follow-up. Median time to complete pain relief was one day; 13 of 18 patients were pain-free within 24 hours.
No SIR-classified adverse events occurred in the cohort. The median dose-length product, a measure of radiation exposure, was 158 mGy·cm (IQR 100–300). The SIR classification system, proposed by the Society of Interventional Radiology Standards of Practice Committee in 2017, provides a standardized framework for grading interventional radiology complications to enable objective comparisons across treatments.
A review published in Cureus on Nov. 22 contextualizes these findings within the expanding use of percutaneous cryoablation for bone tumors. The review notes that cryoablation allows direct visualization of the developing ice ball, which is advantageous for large, irregular, or anatomically sensitive lesions.
The review outlines applications for osteoid osteoma, osteoblastoma, aneurysmal bone cyst, bone metastases, oligometastatic disease, and selected primary malignant bone tumors, while emphasizing that evidence remains heterogeneous and use should be restricted to carefully selected patients after multidisciplinary assessment.
According to the review, CT serves as the main imaging modality for lesions that involve bone structure, while MRI is favored for soft tissue situated near vascular and neural structures. Cryoprobes are typically introduced through bone access trocars under image guidance.
Thorough procedural planning and active tissue protection are indispensable, particularly for lesions situated in the spine, pelvis, and periarticular regions. Follow-up imaging timing and modality should be selected based on the tumor type and therapeutic objective. Although cryoablation is generally considered a safe minimally invasive procedure, complications may occur.